Literature DB >> 33025199

Identification of novel mutations in SARS-COV-2 isolates from Turkey.

Shazia Rehman1,2, Tariq Mahmood3, Ejaz Aziz4, Riffat Batool5.   

Abstract

SARS-CoV-2 was first detected in the city of Wuhan, Hubei Province, China. In this study, we identified 11 unique mutations in viral SARS-COV-2 isolates from Turkey. Nine of them cause structural alterations in the S protein, nsp2, nsp3, nsp4 and nsp12 regions. The mutations identified here might have significant functional implications that need to be addressed in future studies in the context of vaccine engineering and therapeutic interventions. Moreover, transmission and phylogenetic analysis revealed multiple independent sources of introductions of SARS-CoV-2 into Turkey and a close relationship to the isolates from Saudi Arabia.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33025199      PMCID: PMC7538173          DOI: 10.1007/s00705-020-04830-0

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


The first case of the novel coronavirus outbreak in humans was reported in Wuhan, China. The disease was named COVID-19 by WHO, and the virus was named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) by the International Committee on Taxonomy of Viruses [1]. Since the emergence of COVID-19, based on the WHO report of July 8, 2020, more than 11,591,595 confirmed cases were reported in 147 countries, with 537,859 deaths, due to rapidly spreading SARS-CoV-2 [2]. Genetically different coronaviruses are spread in birds, humans and other mammals and can lead to severe diseases of the intestine, liver, nervous system, and respiratory system. Turkey straddles eastern Europe and western Asia and is a major travel hub. According to the World Health Organization's report dated April 24, 2020, Turkey ranks sixth in the European region in terms of COVID-19 disease, after Spain, Italy, Germany, the United Kingdom, and France [3]. The first case of COVID-19 in Turkey was reported on March 11, 2020, and two months after the first case, on May 11, 2020, the Turkish Ministry of Health declared that the number of COVID-19 cases had reached 139,771, with 3841 deaths [4]. In the light of the coronavirus outbreak, the present study was designed with the aim to characterize notable genetic features of SARS-CoV-2 from Turkey and to identify some novel mutations in the spike protein (S), nucleocapsid protein (N), and non-structural proteins (nsp2, nsp3, nsp4, nsp6, nsp12/RdRP). Furthermore, transmission and phylogenetic analysis were also conducted to provide significant insight into the spread of the virus within Turkey. For analysis, a total of 80 genome sequences of virulent strains from Turkey that had been uploaded to the NCBI (https://www.ncbi.nlm.nih.gov/genbank) and GISAID (https://www.gisaid.org/) databases as of May 4, 2020, were retrieved and compared to genome sequences from Saudi Arabia, Iran, America, China, Pakistan, Denmark, Spain, and Italy (Table S1). These sequences were first aligned using the Clustal W program, and a phylogenetic tree was constructed based on this alignment using the maximum-likelihood method in MEGA X software with 1000 replicates [5]. For identification of mutations, sequences of SARS-CoV-2 isolates were compared with a reference sequence (MN908947.1) from Wuhan. The secondary structure of the S protein and nonstructural proteins of SARS-COV-2 was predicted using CFSSP (Chou and Fasman secondary structure prediction), an online server [6]. Based on mutation analysis, 59 out of 80 isolates from Turkey contained a signature 23,403A > G (D614G) mutation in the spike glycoprotein (S), which is clearly indicative of a very frequent mutation (73%). Most samples with the D614G mutation were strongly associated with two other mutations (3037 C > T and 14,408C > T) in ORF1ab region (Table 1). These co-occurring mutations have been described recently as a characteristic of one of the major SARS-CoV-2 variants occurring in Europe. Regarding the ORF 1ab region, we also identified previously reported single-nucleotide polymorphisms (SNPs) at positions 14,408 (C > T), 3037 (C > T), 11,083 (G > T), 1397 (G > A), 18,877 (C > T), 1059 (T > A) and 8782 (C > T). The 14,408C > T (P4715L) and 3037 C > T (F106F) variants in ORF1ab were found to occur at high frequency and are presumed to be linked, causing mutations in the RNA-dependent RNA polymerase (RdRP/nsp12) and nsp3 gene, respectively. RdRP/nsp12 is a key component of the replication/transcription machinery, and therefore, the leucine mutation at position 4715 of RdRP/nsp12 may potentially affect its function, possibly increasing the viral mutation rate. Moreover, the proline-to-leucine mutation was consistently observed in previous reports as a frequent mutation in Europe (51.6%) and North America (58.1%) [7, 8]. The variation C3037T has been reported to cause a synonymous mutation in the region encoding nsp3 and was seen in 57 isolates (71%) from Turkey. Consistent with other studies, C3037T, C14408T and A23403G were the most common mutations (73%) that were found together in isolates from Turkey.
Table 1

Mutations identified in 80 SARS-COV-2 genome sequences from Turkey. Unique mutations in the S protein, nssp2, nsp3, nsp4, nsp12 are indicated by *

MutationsAmino acid changeGeneType of mutationNumber of isolates
23,403 A > GD614GSMissense59
14,408 C > TP4715LORF1abMissense58
3037C > TORF1abSynonymous57
241 C > T5′UTRNon coding42
25563G > TQ57HORF3aMissense31
18877C > TL6205L/L280LORF1abSynonymous29
11083G > TL3606FORF1abMissense25
28688 T > CNSynonymous23
28,881 G > AR203KNMissense23
28882G > ANSynonymous23
28,883 G > CG204RNMissense23
29742G > T3′UTRNon coding22
1397G > AV378IOrf1abMissense21
C26549TMSynonymous13
26735C > TMSynonymous13
884C > AR207SOrf1ab/nsp2Missense11*
8653G > TM2796IOrf1ab/nsp4Missense11*
19839 T > COrf1abSynonymous11
7765C > AOrf1ab/nsp3Synonymous09*
17690C > TS5809LOrf1abMissense08
228C > T5′UTR08
28854C > TS194LNMissense08*
22444C > TD294DSSynonymous08*
2113C > TOrf1ab/nsp2Synonymous07*
12809C > TL4182FORF1abMissense04
10702C > TOrf1abSynonymous04
26551 T > CV10AMMissense04
22964A > TI468VSMissense04*
5736 C > TA1824VOrf1ab/nsp3Missense03*
13476C > TORF1abSynonymous03*
3903C > TP1213LORF1ab/nsp3Missense03*
881G > AA206TORF1ab/nsp2Missense03*
25611C > AORF3aSynonymous03
8782 C > TOrf1abSynonymous02*
1059C > TT265IORF1abMissense02*
23874C > TA771VSMissense02*
25275C > TT1238ISMissense01*
23929C > TY789YSSynonymous01*
22468G > AT302TSSynonymous01*
25314G > TG1251VSMissense01*
2416C > TY717YORF1ab/nsp2Synonymous01*
13730C > TA4489VORF1abMissense01
28144 T > CL84SORF8Missense01
5182 T > CORF1abSynonymous03
27,103 > TA194VMMissense01
5477 C > TH1738YORF1abMissense01
6402C > TP2046LORF1abMissense01
12741C > AT4159KORF1ab/nsp8Missense01
2997C > TS911FORF1abMissense01
13376A > GT4371AORF1abMissense01
19484C > TA6407VORF1abMissense01
1437C > TS391FORF1abMissense01
C7834TORF1abSynonymous01
944G > AG227SORF1abMissense01
26735C > TMSynonymous01
14178C > TORF1abSynonymous01
25549C > TL53FORF3aMissense01
16247C > TA5328VORF1abMissense01
6078C > TA1938VORF1abMissense01
16616C > TT5451IORF1abMissense01
27354A > GORF6Synonymous01
20464G > AD6734NORF1aMissense01
9667 T > CORF1abSynonymous01
29197C > TNSynonymous01
7303C > TORF1abSynonymous01
3464C > TH1067YORF1abMissense01
5192C > TORF1abSynonymous01
20629C > TH6789YORF1abMissense01
20799 T > CORF1abSynonymous01
28391C > TR40CNMissense01
25611C > AORF3aSynonymous03
20668G > AA6802TORF1abMissense01
27476C > TT28IORF7aMissense01
Mutations identified in 80 SARS-COV-2 genome sequences from Turkey. Unique mutations in the S protein, nssp2, nsp3, nsp4, nsp12 are indicated by * Other key variations observed in the present report includes 25,563G > T (Q57H) in ORF3a, along with a consecutive series of three variations at positions 28,881 (G > A), 28,882 (G > A) and 28,883 (G > C) in the N protein. The triple mutation 28,881–28,883, which results in a change of two amino acids, 203–204:RG > KR, is known to play a critical role in virion assembly and structure and had been found frequently in US strains [9]. In present study, this tri-nucleotide mutation in the N protein was observed in eight samples from Turkey, including one from a patient (EPI_ISL_429870) with a history of travel to Saudi Arabia. This mutation was accompanied by the mutations 241:C > T, 3037:C > T and 14,408:C > T. The missense mutation G11083T, conferring an amino acid change from leucine (L) to phenylalanine (F) in non-structural protein 6 (nsp6) at position 3606, was present in 25 samples. It has been observed in Spain, Italy, and Iran, as well in this study (Table S2). Previously, it was reported as an infrequent mutation from Japan, the Netherlands, and Australia [10, 11]. Another substitution (G > A) was found within the region of ORF1a encoding nsp2 at position 1397 and was seen in 26% (21/80) of the isolates, resulting in an amino acid change from valine to isoleucine (V378I) that would not affect the isoelectric point. In a study by Pachetti et al. [8], the V378I substitution was mainly observed in isolates from Oceania and less frequently in Asia and North America. Our secondary structure prediction analysis also highlighted 11 unique mutations in viral SARS-COV-2 isolates from Turkey in the spike (S) protein and non-structural proteins (nsp2, nsp3, nsp4, and nsp12/RdRP) (Table 1). Of these 11 mutations, nine of them have been found to be involved in structural alterations at different sites. Three of them (A771V, T1238I and G1251V) cause alterations in the structure of the S protein, while the rest of them induce structural changes in nsp2 (A206T, R207C, T265I), nsp3 (A1824V), nsp4 (M2796I) and nsp12 (A4489V). Among novel mutants in the S protein, a substitution mutation (I468V) at position 468 was found in four Turkish isolates (EPI_ISL_437316, EPI_ISL_437322, EPI_ISL_437323 and EPI_ISL_437324) in the receptor-binding domain (RBD) of the spike protein that was not reported previously in strains from any other country. At this site, isoleucine (I) was replaced by valine (V) at position 468. Since both amino acids are hydrophobic in nature, having C beta branched residues, this mutation is unlikely to cause a functional change in the protein, as predicted by our secondary structure analysis (Fig. 1a). Nevertheless, if this site is prone to mutate further, it is possible that such mutations could affect the binding of the S protein to ACE2 receptor. Similarly, two strains (EPI_ISL_437314, EPI_ISL_437316) contained a missense mutation at position 771 exchanging alanine (A) for valine (V) in the S protein. Secondary structure predictions demonstrated that this could disrupt the helix structure, favoring a β-sheet at positions 770 and 771 due to addition of (Fig. 1b). The alanine-to-valine substitution as residue 771 was previously seen in one Belgian strain [12].
Fig. 1

Prediction of secondary structure in the S protein, nsp2, nsp3, nsp4, nsp12 regions. a–d Mutations in the S protein. e–g Mutations in nsp2; h–i Mutations in nsp3; j Mutations in nsp4; k Mutations in nsp12. Small rectangular boxes indicate mutated residues Differences in secondary structure between Wuhan and Turkish isolates are indicated by black boxes

Prediction of secondary structure in the S protein, nsp2, nsp3, nsp4, nsp12 regions. a–d Mutations in the S protein. e–g Mutations in nsp2; h–i Mutations in nsp3; j Mutations in nsp4; k Mutations in nsp12. Small rectangular boxes indicate mutated residues Differences in secondary structure between Wuhan and Turkish isolates are indicated by black boxes Additionally, a threonine (polar amino acid)-to-isoleucine (non-polar amino acid) substitution (T1238I) and a change of glycine to a bulkier valine at position 1251 (G1251V) were specifically found in strains EPI_ISL_429870 and EPI_ISL_437317, respectively. A secondary structure prediction revealed that a change of threonine to isoleucine makes this position hydrophobic and favors the formation of an additional helix at position 1238 (Fig. 1c), while the G1251V mutation favors the formation of six additional sheets from position 1448 to 1253 and a helix at site 1254 (Fig. 1d). Earlier reports have suggested that substitution mutations of threonine to isoleucine and alanine to valine in the Ebola virus (EBOV) glycoprotein (GP) increase the infectivity in humans [13, 14]. Therefore, it is possible that the mutant residues at positions 771, 1238 and 1254 in the spike protein of EBOV may lead to an alteration in the way the spike interacts with the receptor, changing the infectivity of the virus, as these mutations lie in the S2 subunit of the S protein. Among the synonymous SNPs in the S protein, the C23929T (Y789Y) mutation was observed in only one Turkish sequence (EPI_ISL_455719) in the S gene. It was reported previously with high prevalence in Indian strains (39.13%) and in one US strain (EPI_ISL_436,898) [7, 12], but not in any other European strains so far. C22444T (S protein) and C28854T substitution (N protein) were observed to be uncommon co-occurring mutations in viral isolates from Turkey (8 samples) and Saudi Arabia (9 samples) (Table S2), which may provide evidence for a travel-associated origin of these mutations. The nsp2 protein is postulated to play an important role in the host cell survival pathway via its interaction with prohibitin (PHB) and prohibitin 2 (PHB2) [15]. The A206T, R207C and T265I mutations were predicted to cause structural alterations within the nsp2 domain (Fig. 1e, f and g). A change of a nonpolar amino acid (alanine) to a polar amino acid (threonine) at position 206 (G881A mutation) in the nsp2 protein resulted in the predicted loss of an α-helix at positions 203, 204 and 206 with the addition of a β-sheet at positions 203 and 204 (Fig. 1e), and this mutation appeared only in three sequences (EPI_ISL_480239, EPI_ISL_428723, EPI_ISL_429863) from Turkey. Similarly, an 884C > T mutation, which resulted in a change of arginine (R) to cysteine (C) at position 207 was present in 11 Turkish isolates and one Pakistani isolate (MT240479.1) (Table S2). The R207C mutation resulted in the replacement of an α-helix with a sheet structure at position 204 and an additional turn at position 210 (Fig. 1f). Furthermore, two Turkish samples (EPI_ISL_437309; EPI_ISL_437315), and one strain each from Spain (EPI_ISL_428688) and Denmark (EPI_ISL_437668) had a T265I mutation, which resulted in the addition of sheet structure at position 266 when threonine is substituted by isoleucine at position 265 (Fig. 1g). Since all of these mutations were identified in the nsp2 domain, possibly causing structural alterations, it is essential to consider the mutational spectrum when designing new antiviral therapeutics targeting the viral ORF1ab. In addition, a synonymous mutation (2416C > T) within nsp2 was found in two infected individuals (EPI_ISL_428712; EPI_ISL_437332) from Turkey with a history of travel from Iran, and in three samples (EPI_ISL_468162; EPI_ISL_468161; EPI_ISL_468160) from Pakistan. Previously, the T265I mutation was detected exclusively in the American population at a frequency of 43% making it a signature SNP for the USA, whereas it was found at very low frequency in Asia (4.8%) [15]. Likewise, a nucleotide change (C > T) was observed at position 2113 in seven Turkish samples and two isolates from Saudi Arabia, but not in any other sequence in this report. In SARS-CoV, nsp3 has been proposed to work with nsp4 and nsp6 to induce double-membrane vesicles (DMVs), which serve as an important component of the replication/transcription complex [16]. In this report, some novel variants in the nsp3 region were also detected at positions 3903 (C > T), 5736 (C > T), and 7765 (C > A). Two of these were missense mutations (C3903Tand C5736T) resulting in a changes from proline to leucine (P1213L) and alanine to valine (A1824V), respectively, and each was exclusively seen in isolates from Turkey, while C7765A was a silent mutation and was observed in 11% (9/80) of Turkish samples and only one viral isolate from Saudi Arabia (EPI_ISL_437463) (Table S2). In mutant A1824V, there is a loss of a turn and the addition of a sheet structure at position 1825 (Fig. 1h) that might have significant functional implications, whereas no substantial change in secondary structure was observed for mutant P1213L (Fig. 1i). It is important to evaluate these mutations in nsp3, as this gene has been reported to harbour many mutations that resulted in the evolution of betacoronaviruses with extensive selection pressure [17]. Apart from frequent mutations, two mutations in the nsp4 gene (C8782T and G8653T) and one in the nsp12/RdRP gene (13,730C > T) were found to be completely unique to Turkey. A silent mutation at position 8782 (C > T) within nsp4 was found in two infected individuals (EPI_ISL_428718 and EPI_ISL_437317) from Turkey and in seven samples from Spain, where it was an infrequent mutation; however, it was present at high frequency in isolates from Oceania and North America in previous reports [8]. The G8653T mutation in the nsp4 gene, resulting in a change of methionine (M) to isoleucine (I) at position 2796 was found in 11 Turkish strains but not observed in any other viral isolates from Europe so far. However, this mutation was detected by Joshi and Paul [18] in nine Indian samples and in two isolates from Kuwait. In the nsp12/RdRP region, an alanine/valine substitution was observed at site 4489 in a single sequence (EPI_ISL_455719, Turkey/Mardin) on April 9, 2020, that was not found in any other sequence in this report. In a previous report by Maitra et al. [19], this unique mutation was also found in two infected individuals in India. Further, our secondary structure prediction analysis showed that the M2796I mutation causes changes in the secondary structure of nsp4 in which the α-helix is replaced with a β-sheet structure at position 2795 and a turn at position 2798 (Fig. 1j), which might affect the interaction between nsp3 and nsp4 and thus the replication of the virus. The side chain of valine is larger than that of alanine, and substitution of valine in nsp12 resulted in the potential loss of an α-helix at positions 4486, 4487, and 4488 with the addition of a β-sheet from positions 4486 to 4490 (Fig. 1k). Therefore, this substitution might have functional consequences that can potentially affect the replication and mutagenic capability of SARS-CoV-2. Importantly, it would be interesting to investigate the effects of these substitutions in the non-structural proteins, as one of a previous study has suggested that an alanine-to-valine substitution in the non-structural protein NS2A of Zika virus impairs viral RNA synthesis and results in attenuation of the virus [20]. Similarly, a valine substitution in the RdRP protein in Indian SARS-CoV-2 isolates has been shown to cause a structural alteration that impairs packing of the protein [21]. Thus, functional characterization of the mutations investigated in our study needs to be carried out to understand their role and to develop strategies for vaccine design. We found that 13 viral isolates from Turkey harboring 23,403 A > G, 3037 C > T, and 14,408 C > T mutations were from individuals who had a history of travel from Saudi Arabia (Table 2). Of these, six cases were reported from the city of Ankara while the remaining ones were from Aksaray, Sakarya, Tekirdag, Kocaeli, Kastamonu, Konya and Afyon. Similarly, six samples were from individuals who had a history of travel from Iran and most of these cases (5/6) were from Istanbul and were listed in GISAID. Among Iran-travel-linked isolates, four samples (EPI_ISL_437319, EPI_ISL_437324, EPI_ISL_437325, and EPI_ISL_437327) contain the mutations (G1397A, T28688C and G29742T, a Europe-based introduction), while the remaining two samples (EPI_ISL_437326 and EPI_ISL_437332) lacked these mutations (Table 2). However, the G1397A and T28688C substitutions were also observed in one patient who had travelled to Taiwan. This suggests that COVID-19 infection spread to Turkey from multiple countries, especially from Saudi Arabia and Iran. In a similar analysis, Eden et al. [22] provided evidence of SARS-CoV-2 being exported to Australia from Iran. Our findings may also contribute to a better understanding of the diversity of circulating SARS-COV-2 strains and origin of imported cases in Turkey.
Table 2

List of Turkish strains from individuals with a history of travel

Accession noVirus nameLocationCollection dateTravel history
EPI_ISL_429866hCoV-19/Turkey/HSGM-4236/2020Turkey / Afyon/west2020–03-16Saudi Arabia
EPI_ISL_429869hCoV-19/Turkey/HSGM-4701/2020Turkey / Konya2020–03-17Saudi Arabia
EPI_ISL_428716hCoV-19/Turkey/HSGM-5711/2020Turkey / Ankara2020–03-18Saudi Arabia
EPI_ISL_428714hCoV-19/Turkey/HSGM-5602/2020Turkey / Kastamonu2020–03-18Saudi Arabia
EPI_ISL_429862hCoV-19/Turkey/HSGM-8970/2020Turkey / Ankara2020–03-22Saudi Arabia
EPI_ISL_437332hCoV-19/Turkey/HSGM-4698/2020Turkey / Istanbul2020–03-18Iran
EPI_ISL_428718hCoV-19/Turkey/HSGM-5770/2020Turkey / Kocaeli2020–03-19Saudi Arabia
EPI_ISL_437328hCoV-19/Turkey/HSGM-7668/2020Turkey / Tekirdag2020–03-19Saudi Arabia
EPI_ISL_437326hCoV-19/Turkey/HSGM-1432/2020Turkey / Istanbul2020–03-19Iran
EPI_ISL_437325hCoV-19/Turkey/HSGM-1495/2020Turkey / Istanbul2020–03-19Iran
EPI_ISL_437324hCoV-19/Turkey/HSGM-1476/2020Turkey / Istanbul2020–03-19Iran
EPI_ISL_437327hCoV-19/Turkey/HSGM-1458/2020Turkey / Agri2020–03-19Iran
EPI_ISL_437323hCoV-19/Turkey/HSGM-1481/2020Turkey / Istanbul2020–03-19Taiwan
EPI_ISL_437319hCoV-19/Turkey/HSGM-1490/2020Turkey / Istanbul2020–03-19Iran
EPI_ISL_429870hCoV-19/Turkey/HSGM-8990/2020Turkey / Sakarya2020–03-22Saudi Arabia
EPI_ISL_428723hCoV-19/Turkey/HSGM-8964/2020Turkey / Aksaray2020–03-22Saudi Arabia
EPI_ISL_429871hCoV-19/Turkey/HSGM-10241/2020Turkey / Ankara2020–03-23Saudi Arabia
EPI_ISL_437317hCoV-19/Turkey/HSGM-1027/2020Turkey / Ankara2020–03-27Saudi Arabia
EPI_ISL_437329hCoV-19/Turkey/HSGM-6204/2020Turkey / Ankara2020–03-19Saudi Arabia
EPI_ISL_437331hCoV-19/Turkey/HSGM-1014/2020Turkey / Ankara2020–03-25Saudi Arabia
List of Turkish strains from individuals with a history of travel Phylogenetic analysis of SARS-COV-2 genome sequences suggested that the Turkish strain is closely related to isolates from Saudi Arabia, suggesting a common origin (Fig. 2). However, the sequences from Turkey were dispersed throughout the phylogenetic tree, indicating multiple independent introductions into the country. In the phylogram, two distinct clades were categorized as cluster 1 and cluster 2. Cluster 1 contained the mutations 1397G > A, 11,083G > T, 28,688 T > C, and 29,742G > T, while the second cluster had 23,403 A > G, 3037 C > T, and 14,408 C > T as the dominant mutations. Moreover, the majority of viral isolates in Turkey showed L type characteristics and formed a monophyletic clade, while the S type was present in limited numbers. An SNP with “T” at position 28,144 encoding leucine was classified as L type, while “C” at this position encoding serine is referred as S type. It has been suggested that the L type is more aggressive and contagious than the S type [12]. Thus, it appears that the L type is predominant in the Turkish population. In addition, samples having travel connection to Saudi Arabia and Iran showed a monophyletic origin within their respective clusters in the phylogenetic tree.
Fig. 2

Sub-tree showing the informative branch containing imported cases to Turkey from Saudi Arabia (indicated by red squares) and Iran (indicated by green triangles)

Sub-tree showing the informative branch containing imported cases to Turkey from Saudi Arabia (indicated by red squares) and Iran (indicated by green triangles) In conclusion, functional characterization of novel mutations investigated in our study needs to be carried out to understand the exact role of these variations. Furthermore, awareness of the above-mentioned mutations might be useful for the identification of less-virulent strains and the development of vaccines against a large repertoire of strains. Phylogenetic and transmission analysis revealed that the spread of SARS-COV-2 to Turkey was due to multiple independent introductions and that viral isolates from Saudi Arabia and Turkey are closely related to one another. Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 146 kb)
  15 in total

1.  MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets.

Authors:  Sudhir Kumar; Glen Stecher; Koichiro Tamura
Journal:  Mol Biol Evol       Date:  2016-03-22       Impact factor: 16.240

2.  Different effects of two mutations on the infectivity of Ebola virus glycoprotein in nine mammalian species.

Authors:  Yohei Kurosaki; Mahoko Takahashi Ueda; Yusuke Nakano; Jiro Yasuda; Yoshio Koyanagi; Kei Sato; So Nakagawa
Journal:  J Gen Virol       Date:  2018-01-04       Impact factor: 3.891

3.  Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant.

Authors:  Maria Pachetti; Bruna Marini; Francesca Benedetti; Fabiola Giudici; Elisabetta Mauro; Paola Storici; Claudio Masciovecchio; Silvia Angeletti; Massimo Ciccozzi; Robert C Gallo; Davide Zella; Rudy Ippodrino
Journal:  J Transl Med       Date:  2020-04-22       Impact factor: 5.531

4.  Two-amino acids change in the nsp4 of SARS coronavirus abolishes viral replication.

Authors:  Yusuke Sakai; Kengo Kawachi; Yutaka Terada; Hiroko Omori; Yoshiharu Matsuura; Wataru Kamitani
Journal:  Virology       Date:  2017-07-21       Impact factor: 3.616

5.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.

Authors: 
Journal:  Nat Microbiol       Date:  2020-03-02       Impact factor: 17.745

6.  Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy.

Authors:  Domenico Benvenuto; Silvia Angeletti; Marta Giovanetti; Martina Bianchi; Stefano Pascarella; Roberto Cauda; Massimo Ciccozzi; Antonio Cassone
Journal:  J Infect       Date:  2020-04-10       Impact factor: 6.072

7.  An emergent clade of SARS-CoV-2 linked to returned travellers from Iran.

Authors:  John-Sebastian Eden; Rebecca Rockett; Ian Carter; Hossinur Rahman; Joep de Ligt; James Hadfield; Matthew Storey; Xiaoyun Ren; Rachel Tulloch; Kerri Basile; Jessica Wells; Roy Byun; Nicky Gilroy; Matthew V O'Sullivan; Vitali Sintchenko; Sharon C Chen; Susan Maddocks; Tania C Sorrell; Edward C Holmes; Dominic E Dwyer; Jen Kok
Journal:  Virus Evol       Date:  2020-04-10

8.  Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility.

Authors:  Arindam Maitra; Mamta Chawla Sarkar; Harsha Raheja; Nidhan K Biswas; Sohini Chakraborti; Animesh Kumar Singh; Shekhar Ghosh; Sumanta Sarkar; Subrata Patra; Rajiv Kumar Mondal; Trinath Ghosh; Ananya Chatterjee; Hasina Banu; Agniva Majumdar; Sreedhar Chinnaswamy; Narayanaswamy Srinivasan; Shanta Dutta; Saumitra DAS
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

9.  Mutational spectra of SARS-CoV-2 orf1ab polyprotein and signature mutations in the United States of America.

Authors:  Shuvam Banerjee; Sohan Seal; Riju Dey; Kousik Kr Mondal; Pritha Bhattacharjee
Journal:  J Med Virol       Date:  2020-08-25       Impact factor: 20.693

View more
  8 in total

1.  Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: From alpha to Omicron.

Authors:  Choo Yee Yu; Sie Yeng Wong; Nancy Woan Charn Liew; Narcisse Joseph; Zunita Zakaria; Isa Nurulfiza; Hui Jen Soe; Rachna Kairon; Syafinaz Amin-Nordin; Hui Yee Chee
Journal:  Front Med (Lausanne)       Date:  2022-09-23

2.  Insights on the SARS-CoV-2 genome variability: the lesson learned in Brazil and its impacts on the future of pandemics.

Authors:  Victória Riquena Grosche; Igor Andrade Santos; Giulia Magalhães Ferreira; João Victor Rodrigues Dutra; Larissa Catharina Costa; Nilson Nicolau-Junior; Artur Trancoso Lopo Queiroz; Diego Pandeló José; Ana Carolina Gomes Jardim
Journal:  Microb Genom       Date:  2021-11

3.  Epidemiological associations with genomic variation in SARS-CoV-2.

Authors:  Ali Rahnavard; Tyson Dawson; Rebecca Clement; Nathaniel Stearrett; Marcos Pérez-Losada; Keith A Crandall
Journal:  Sci Rep       Date:  2021-11-26       Impact factor: 4.379

4.  Persistence of infectious SARS-CoV-2 particles for up to 37 days in patients with mild COVID-19.

Authors:  Tobias Zahn; Ines Mhedhbi; Sascha Hein; Jan Raupach; Csaba Miskey; Younes Husria; Kathrin Bayanga; Detlef Bartel; Stefan Vieths; Zoltan Ivics; Doris Oberle; Brigitte Keller-Stanislawski; Marie-Luise Herrlein; Thorsten Jürgen Maier; Eberhard Hildt
Journal:  Allergy       Date:  2021-10-24       Impact factor: 14.710

5.  Genome sequence analysis of SARS-COV-2 isolated from a COVID-19 patient in Erbil, Iraq.

Authors:  Bashdar Mahmud Hussen; Dana Khdr Sabir; Yasin Karim; Karzan Khawaraham Karim; Hazha Jamal Hidayat
Journal:  Appl Nanosci       Date:  2022-02-07       Impact factor: 3.869

6.  Genomic Snapshot of SARS-CoV-2 in Migrants Entering Through Mediterranean Sea Routes.

Authors:  Nicole Grandi; Bianca Paglietti; Roberto Cusano; Gabriele Ibba; Vincenzo Lai; Claudia Piu; Flavia Angioj; Caterina Serra; David J Kelvin; Enzo Tramontano; Salvatore Rubino
Journal:  Front Public Health       Date:  2022-03-03

7.  Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease.

Authors:  Vasundara Srinivasan; Hévila Brognaro; Prince R Prabhu; Edmarcia Elisa de Souza; Sebastian Günther; Patrick Y A Reinke; Thomas J Lane; Helen Ginn; Huijong Han; Wiebke Ewert; Janina Sprenger; Faisal H M Koua; Sven Falke; Nadine Werner; Hina Andaleeb; Najeeb Ullah; Bruno Alves Franca; Mengying Wang; Angélica Luana C Barra; Markus Perbandt; Martin Schwinzer; Christina Schmidt; Lea Brings; Kristina Lorenzen; Robin Schubert; Rafael Rahal Guaragna Machado; Erika Donizette Candido; Danielle Bruna Leal Oliveira; Edison Luiz Durigon; Stephan Niebling; Angelica Struve Garcia; Oleksandr Yefanov; Julia Lieske; Luca Gelisio; Martin Domaracky; Philipp Middendorf; Michael Groessler; Fabian Trost; Marina Galchenkova; Aida Rahmani Mashhour; Sofiane Saouane; Johanna Hakanpää; Markus Wolf; Maria Garcia Alai; Dusan Turk; Arwen R Pearson; Henry N Chapman; Winfried Hinrichs; Carsten Wrenger; Alke Meents; Christian Betzel
Journal:  Commun Biol       Date:  2022-08-11

8.  The First Molecular Characterization of Serbian SARS-CoV-2 Isolates From a Unique Early Second Wave in Europe.

Authors:  Danijela Miljanovic; Ognjen Milicevic; Ana Loncar; Dzihan Abazovic; Dragana Despot; Ana Banko
Journal:  Front Microbiol       Date:  2021-06-18       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.